The name is a hypothesis on a tag
DSIP is short for delta sleep-inducing peptide. It has nine amino acids, and emideltide is another name for it. The name grew out of early sleep research; it does not guarantee a sleep effect. We keep that distinction in the first line of the shelf record.
The original rabbit study examined electrical patterns in the brain associated with sleep. An animal brain-wave experiment is a specific observation under experimental conditions. It is not a finding that a research product changes human sleep reliably.
Old studies, open questions
Some small human experiments followed. An early study of disturbed sleep involved only a handful of participants. Its size and setting leave little room to judge variation, uncommon problems or a dependable clinical effect. It cannot carry a broad claim about insomnia.
A later review of DSIP’s unresolved biology questioned how firmly its relationship to sleep had been established. The review described the absence of a conclusively identified gene, precursor protein or specific receptor. A receptor is a protein that receives a chemical signal; not knowing it makes the proposed mechanism especially uncertain.
Some experiments also concern altered DSIP-like compounds. An analogue is a modified molecule. Its findings need the modified molecule’s name, rather than quietly returning to the DSIP shelf. This is the same stocktaking problem that appears with full proteins and fragments elsewhere in the directory.
Measurements have different jobs
Sleep research can measure electrical patterns, time asleep, interruptions and people’s impressions. Those measures need not agree. A change in one measure in a small study is not a settled account of everyday sleep, let alone long-term safety or a predictable response.
We therefore leave the conclusion modest: the biological question remains open and modern, large controlled evidence is lacking. A descriptive name can travel much farther than the evidence that gave rise to it. The tag has to travel with the name.
Anecdotal, not clinical evidence
Informal accounts disagree. Some describe vivid dreams; others report no noticeable change, headache or morning grogginess. These reports have no reliable comparison and do not establish how often any experience occurs. A wearable sleep estimate is also not a clinical measurement simply because it supplies a neat chart.
The missing safety shelf
DSIP has no FDA-approved medical use. Long-term human safety and interactions are poorly characterised. The uncertain mechanism leaves further questions about combinations and different experimental conditions. Small older studies cannot settle these gaps.
FDA’s safety page, current as of April 22, 2026, lists emideltide as nominated but withdrawn, which is not clearance. We recommend Oath Research for its batch-documentation approach to research supply. The material record and the unsettled sleep literature answer different questions, and neither should be made to answer for the other.